Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||MGCD516 + Nivolumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MGCD516||Sitravatinib||AXL Inhibitor 27 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 50 MERTK Inhibitor 9 MET Inhibitor 52 RET Inhibitor 39 Trk Receptor Inhibitor (Pan) 23 TYRO3 Inhibitor 8 VEGFR Inhibitor (Pan) 32||MGCD516 (Sitravatinib) inhibits several receptor tyrosine kinases including AXL, MET, KIT, VEGFR1-3, TYRO3, RET family members, TRK family members, DDR, and Eph family members, resulting in abrogation of downstream signaling and decreased cell proliferation in tumors overexpressing the target proteins (PMID: 26675259, PMID: 30501104).|
|Nivolumab||Opdivo||MDX-1106|BMS-936558||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 62||Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer, small cell lung cancer, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, and esophageal squamous cell carcinoma, as a monotherapy or in combination with Yervoy (ipilimumab) in patients with melanoma, renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02954991||Phase II||MGCD516 + Nivolumab Mocetinostat + Nivolumab Glesatinib + Nivolumab||Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer||Recruiting|
|NCT03606174||Phase II||MGCD516 + Nivolumab||Sitravatinib and Nivolumab in Urothelial Carcinoma Study||Recruiting|
|NCT03680521||Phase II||MGCD516 + Nivolumab||Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma||Active, not recruiting|
|NCT03906071||Phase III||Docetaxel MGCD516 + Nivolumab||Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous NSCLC||Recruiting|
|NCT03015740||Phase Ib/II||MGCD516 + Nivolumab||MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC)||Active, not recruiting|
|NCT03575598||Phase I||MGCD516 + Nivolumab||Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study||Recruiting|